Diplomat Pharmacy Inc. (NYSE:DPLO) was downgraded by investment analysts at Credit Suisse Group AG to an “underperform” rating in a research report issued on Wednesday.

Several other equities analysts have also recently weighed in on DPLO. Zacks Investment Research cut shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research report on Wednesday, November 2nd. Leerink Swann cut shares of Diplomat Pharmacy from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $35.00 to $18.00 in a research report on Thursday, November 3rd. Cowen and Company dropped their price target on shares of Diplomat Pharmacy from $37.00 to $18.00 and set a “market perform” rating on the stock in a research report on Thursday, November 3rd. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Diplomat Pharmacy in a research report on Thursday, November 3rd. Finally, Barclays PLC reaffirmed a “buy” rating and issued a $23.00 price target on shares of Diplomat Pharmacy in a research report on Thursday, November 3rd. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $26.56.

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Diplomat Pharmacy (NYSE:DPLO) opened at 14.46 on Wednesday. The firm has a market cap of $961.75 million, a P/E ratio of 29.81 and a beta of 1.21. Diplomat Pharmacy has a 12 month low of $12.47 and a 12 month high of $38.94. The firm’s 50-day moving average price is $22.02 and its 200-day moving average price is $30.24.

Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings results on Wednesday, November 2nd. The company reported $0.21 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.24 by $0.03. Diplomat Pharmacy had a return on equity of 10.47% and a net margin of 0.77%. The business had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.26 billion. During the same quarter in the previous year, the business posted $0.26 earnings per share. The business’s revenue was up 24.7% on a year-over-year basis. On average, equities research analysts expect that Diplomat Pharmacy will post $0.84 EPS for the current fiscal year.

In related news, EVP Atheer A. Kaddis sold 20,000 shares of Diplomat Pharmacy stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $30.12, for a total value of $602,400.00. Following the completion of the transaction, the executive vice president now directly owns 20,000 shares in the company, valued at approximately $602,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 35.40% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in Diplomat Pharmacy by 9.5% in the second quarter. Vanguard Group Inc. now owns 3,334,010 shares of the company’s stock worth $116,690,000 after buying an additional 289,571 shares in the last quarter. BlackRock Fund Advisors raised its position in Diplomat Pharmacy by 18.3% in the third quarter. BlackRock Fund Advisors now owns 3,180,902 shares of the company’s stock worth $89,097,000 after buying an additional 492,922 shares in the last quarter. Wells Fargo & Company MN raised its position in Diplomat Pharmacy by 2.2% in the third quarter. Wells Fargo & Company MN now owns 2,493,518 shares of the company’s stock worth $69,843,000 after buying an additional 54,413 shares in the last quarter. Capital World Investors raised its position in Diplomat Pharmacy by 21.3% in the third quarter. Capital World Investors now owns 2,385,000 shares of the company’s stock worth $66,804,000 after buying an additional 418,400 shares in the last quarter. Finally, TimesSquare Capital Management LLC raised its position in Diplomat Pharmacy by 11.3% in the third quarter. TimesSquare Capital Management LLC now owns 1,561,700 shares of the company’s stock worth $43,743,000 after buying an additional 158,245 shares in the last quarter. Institutional investors and hedge funds own 76.77% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Diplomat Pharmacy Inc. (DPLO) Cut to Underperform at Credit Suisse Group AG” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2016/11/23/diplomat-pharmacy-inc-dplo-cut-to-underperform-at-credit-suisse-group-ag.html.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions.

5 Day Chart for NYSE:DPLO

Receive News & Stock Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related stocks with our FREE daily email newsletter.